MDWD
MediWound Ltd.
stockNASDAQ
mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound's first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 13.52 | 2026-10-02 | -7.17% | 1.772 |
| 1M | 13.84 | 2026-09-09 | -9.32% | -0.229 |
| 3M | 14.71 | 2026-07-09 | -14.68% | 0.085 |
| 6M | 17.77 | 2026-04-09 | -29.38% | 0.211 |
| 1Y | 17.90 | 2025-10-09 | -29.89% | 0.617 |
| 2Y | 16.50 | 2024-10-09 | -23.94% | — |
| 5Y | 22.19 | 2021-10-08 | -43.44% | 0.717 |
MediWound Ltd. (NASDAQ:MDWD) stock price today is $12.55, and today's volume is 82,560. MDWD is up 1.047% today. The 30 day average volume is 98,584. MDWD market cap is $162.02M with 12.91M shares outstanding.